Welcome to our dedicated page for In8Bio SEC filings (Ticker: INAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IN8bio, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing γδ T cell therapies and γδ T cell engagers. Form 8-K reports cover operating and financial results, clinical updates for INB-200 and INB-400 in newly diagnosed glioblastoma, preclinical γδ T cell engager data, financing and capital-structure matters, and governance events.
Proxy materials describe annual-meeting voting matters, director elections, auditor ratification, equity incentive plan proposals, board oversight, executive compensation, and stockholder governance. The filings also identify INAB common stock registered on Nasdaq and provide formal records of material events affecting the company's pipeline, financing, and corporate governance.
IN8bio, Inc. reported fourth quarter and full-year 2025 results, highlighting clinical progress in glioblastoma, a strengthened balance sheet and lower losses. Repeat dosing of its DeltEx DRI γδ T cells in newly diagnosed GBM achieved median progression-free survival of 13.0 months versus 6.6 months for a standard-of-care cohort, with no dose-limiting toxicities or serious unexpected safety issues reported.
The company closed an initial $20.1 million tranche of a private placement of up to $40.2 million, with net proceeds of $18.5 million expected to extend its cash runway into the first half of 2027. Cash was $27.1 million as of December 31, 2025, up from $11.1 million a year earlier. Full-year net loss narrowed to $19.4 million, or $4.44 per share, from $30.4 million, or $17.05 per share, driven by lower R&D and G&A expenses.
IN8bio is advancing its INB-200/400 GBM programs, INB-100 for high-risk leukemias, and the INB-600 γδ T cell engager platform, including INB-619 heading into IND-enabling studies. The company outlined multiple 2026 milestones, including FDA guidance on regulatory pathways, additional GBM data and initial INB-619 animal data.
IN8BIO, Inc. reports that Laurence W. Lytton and the Lytton-Kambara Foundation each beneficially own 9.99% of Common Stock, consisting of 984,031 shares reported for each holder.
The filing states that the reported holdings "consist of 900,000 shares of Common Stock and warrants to purchase 1,092,753 shares of Common Stock, subject to a 9.99% beneficial ownership limitation," and that the percentage was calculated based on 9,766,132 shares outstanding as of January 12, 2026, per a prospectus dated January 28, 2026.
IN8bio, Inc. reported that director Alan S. Roemer has notified the Board of his decision to resign from the Board and from the Audit and Compensation Committees, effective February 28, 2026. The company states that his resignation is not due to any disagreement with IN8bio, its management, the Board, or any Board committee on matters related to operations, policies, or practices.
The Board has appointed independent director Jeremy Graff as Interim Chair of the Board, effective the same date. This change reflects a governance and leadership transition at the Board level without any financial results or major transactions described in this report.
IN8bio, Inc. received a Schedule 13G showing that Alyeska Investment Group, Alyeska Fund GP, and Anand Parekh beneficially own 966,381 shares of common stock, representing 9.9% of the class as of December 31, 2025. The group reports no sole voting or dispositive power, but shared power over all reported shares.
The filing explains that Alyeska-related entities hold common stock, PIPE shares, and warrants, but the warrants are subject to a 9.9% ownership cap. Based on 9,761,425 IN8bio shares outstanding, the reporting persons certify the holdings were acquired in the ordinary course and not to influence control.
IN8bio, Inc. announced that its Board of Directors appointed Chief Operating Officer Kate Rochlin as President of the company, effective February 4, 2026. She will hold both roles of President and Chief Operating Officer, providing continuity in executive leadership. The company notes that there are no family relationships or related-party transactions involving Dr. Rochlin that require disclosure under the SEC’s executive and related-party rules.
IN8bio, Inc. (INAB) reported an option grant to executive Lawrence Lamb, EVP and CSO. On February 4, 2026, he received 72,000 employee stock options with a $1.96 exercise price, all held directly. Twenty-five percent vest on February 4, 2027, with the remaining options vesting in 36 equal monthly installments, contingent on his continued service.
IN8bio, Inc. (INAB) granted its Chief Financial Officer, McCall Patrick, a new stock option award. On February 4, 2026, the CFO received an employee stock option to purchase 75,000 shares of common stock at an exercise price of $1.96 per share.
These options were awarded at no cost and are held directly. Twenty-five percent of the shares vest on February 4, 2027, and the remaining shares vest in 36 equal monthly installments afterward, as long as the CFO continues to provide service through each vesting date.
IN8bio, Inc. reported an equity award to its President and COO, Kate Rochlin, on a Form 4. On February 4, 2026, she received an employee stock option covering 80,000 shares of common stock at an exercise price of $1.96 per share, held directly.
The option expires on February 4, 2036. Vesting is time-based: 25% of the option vests on February 4, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent on her continued service with the company.
IN8bio, Inc. (INAB) reported a new stock option grant to CEO, director and 10% owner William Tai-Wei Ho. On February 4, 2026, he received an employee stock option covering 206,000 shares of common stock at an exercise price of $1.96 per share, expiring February 4, 2036.
According to the vesting terms, 25% of the option shares vest on February 4, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, as long as he continues to provide service through each vesting date. Following this grant, he beneficially owns 206,000 derivative securities directly.
IN8bio, Inc. has filed a resale prospectus covering up to 14,384,052 shares of common stock for sale by existing investors, and the company will not receive any proceeds from these sales. The shares relate to a December 22, 2025 private placement of 4,931,375 PIPE Shares and 9,452,677 shares issuable on exercise of pre-funded warrants.
The pre-funded warrants are immediately exercisable at $0.0001 per share, subject to beneficial ownership limits of up to 19.99%. IN8bio previously received approximately $18.6 million in net proceeds from the initial private placement closing. The stock trades on Nasdaq Capital Market under the symbol INAB.